外泌体在多发性骨髓瘤中的应用:从基础到临床
多发性骨髓瘤(MM)仍不可治愈,骨髓微环境保护MM细胞并容纳骨吸收和免疫抑制等症状。外泌体(<150 nm的细胞外囊泡)携带蛋白和RNA参与骨溶解、血管生成、免疫抑制和耐药,靶向外泌体分泌或利用其递送毒性载荷及作为液体活检生物标志物是潜在方向。
要点
- 外泌体是<150 nm的细胞外囊泡,由MM细胞等分泌并递送蛋白和RNA至受体细胞。
- 外泌体参与MM的骨溶解、血管生成、免疫抑制和耐药等过程。
- 靶向外泌体分泌或利用其递送毒性载荷、作为液体活检生物标志物是研究中的策略。
核心结论
- 外泌体参与多发性骨髓瘤骨髓微环境中的骨溶解、血管生成、免疫抑制和耐药等过程,靶向外泌体分泌或利用其递送毒性载荷及作为液体活检生物标志物是潜在方向。
研究设计与样本
- 综述,总结外泌体在多发性骨髓瘤骨髓中相关过程的研究发现、当前治疗策略及临床研究概况。
主要发现
- 外泌体为<150 nm的囊泡,由包括MM细胞在内的不同细胞类型分泌,携带蛋白和RNA货物递送至受体细胞。
- 外泌体参与MM相关的骨溶解、血管生成、免疫抑制和耐药等过程。
- 靶向外泌体分泌可能阻断上述不同过程。
- 外泌体可被利用来递送毒性载荷。
- 临床研究探索细胞外囊泡货物作为液体活检中潜在MM生物标志物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) remains an incurable plasma cell malignancy that develops in the bone marrow (BM). This BM is partially responsible for protecting the MM cells against current standard-of-care therapies and for accommodating MM-related symptoms such as bone resorption and immune suppression. Increasing evidence has implicated extracellular vesicles (EV), including exosomes in the different processes within the BM. Exosomes are <150-nm-sized vesicles secreted by different cell types including MM cells. These vesicles contain protein and RNA cargo that they deliver to the recipient cell. In this way, they have been implicated in MM-related processes including osteolysis, angiogenesis, immune suppression, and drug resistance. Targeting exosome secretion could therefore potentially block these different processes. In this review, we will summarize the current findings of exosome-related processes in the BM and describe not only the current treatment strategies to counter them but also how exosomes can be harnessed to deliver toxic payloads. Finally, an overview of the different clinical studies that investigate EV cargo as potential MM biomarkers in liquid biopsies will be discussed.
引用
- Menu E, Vanderkerken K. Exosomes in multiple myeloma: from bench to bedside. Blood. 2022. PMID: 35271699. doi:10.1182/blood.2021014749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。